ProQR Therapeutics N.V. (PRQR)
1.15
0.01 (0.88%)
At close: Apr 17, 2025, 3:59 PM
1.23
7.29%
After-hours: Apr 17, 2025, 07:55 PM EDT
0.88% (1D)
| Bid | 1.11 |
| Market Cap | 120.99M |
| Revenue (ttm) | 18.96M |
| Net Income (ttm) | -27.81M |
| EPS (ttm) | -0.35 |
| PE Ratio (ttm) | -3.29 |
| Forward PE | -2.3 |
| Analyst | Buy |
| Ask | 1.42 |
| Volume | 443,151 |
| Avg. Volume (20D) | 507,206 |
| Open | 1.16 |
| Previous Close | 1.14 |
| Day's Range | 1.12 - 1.19 |
| 52-Week Range | 1.07 - 4.62 |
| Beta | 0.24 |
About PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2014
Employees 166
Stock Exchange NASDAQ
Ticker Symbol PRQR
Website https://www.proqr.com
Analyst Forecast
According to 6 analyst ratings, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 726.09% from the latest price.
Stock ForecastsNext Earnings Release
ProQR Therapeutics N.V. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+5.6%
ProQR Therapeutics shares are trading higher afer ...
Unlock content with
Pro Subscription
8 months ago
+12.57%
Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
